Medication info
Janugluem XR Extended-Release Tablets 50/500 mg

Janugluem XR Extended-Release Tablets 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Samchundang Pharm. Co., Ltd.
Appearance
Pale blue, double convex, oval-shaped extended-release film-coated tablets
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300593 · Approved 2023.02.17 · Insurance code 651205960

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin. The dose should be increased gradually. Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: For patients with no prior experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin therapy: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients who were taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with this drug 50/1000 mg extended-release tablets at a dose of 2 tablets once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Samchundang Pharm. Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication assists patients with type 2 diabetes in effecting better blood sugar control. Sitagliptin and Metformin work together to allow for stable management of blood sugar levels when used along with dietary adjustments and exercise therapy. It is recommended as an adjunctive treatment for those who find it difficult to control their blood sugar levels. If taken consistently, it may provide positive assistance in blood sugar control.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin. The dose should be increased gradually. Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: For patients with no prior experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin therapy: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients who were taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with this drug 50/1000 mg extended-release tablets at a dose of 2 tablets once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication contains Sitagliptin and Metformin and is used for the treatment of diabetes. Firstly, Sitagliptin can rarely cause serious allergic reactions such as anaphylaxis, angioedema, and skin rash. If any of these symptoms occur, immediate discontinuation of the medication and consultation with a physician is necessary. Additionally, Sitagliptin may induce acute pancreatitis, so careful observation for symptoms of pancreatitis, such as abdominal pain, nausea, and vomiting, is required. If suspected, the medication should be discontinued. Metformin can cause lactic acidosis, a rare but very serious side effect. Lactic acidosis can begin with nonspecific symptoms such as muscle pain, difficulty breathing, weakness, and abdominal pain; therefore, both patients and caregivers should be well informed about these symptoms and report them to a physician immediately if they occur. This medication should not be given to patients with moderate to severe renal impairment, acute heart failure, severe infections, dehydration, liver dysfunction, or to women during pregnancy or lactation. Moreover, the use of this medication should be temporarily suspended for a period before and after surgery, and should be restarted only after renal function has been confirmed to be normal. This medication presents a risk of hypoglycemia; therefore, caution is advised in cases of irregular meal timing, excessive physical activity, and concomitant use with other hypoglycemic agents, and immediate appropriate action should be undertaken if hypoglycemic symptoms arise. Furthermore, this medication contains Red 40 dye, which can induce allergic reactions; hence, patients with hypersensitivity to this ingredient should use it cautiously. Regular monitoring of kidney function and blood tests is essential for safety, and vitamin B12 levels may decrease and may require supplementation if necessary. Finally, alcohol consumption should be avoided while taking this medication, and if any unusual symptoms or suspected side effects arise during administration, consultation with a healthcare professional should be sought immediately.

Side effects

  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 16 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • blistering similar to pemphigus
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture and must be stored in a tightly sealed container. It is best to keep it at room temperature between 1 and 30 degrees Celsius. This will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Pale blue, double convex, oval-shaped extended-release film-coated tablets

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.